Neuroinflammation is a critical pathological feature of Progressive Supranuclear Palsy (PSP), though its role differs from other neurodegenerative tauopathies. In PSP, neuroinflammatory responses are characterized by distinct microglial activation patterns, unique cytokine profiles, and regional specificity that correlates with tau pathology burden [1][2]. Understanding these neuroimmune differences provides insights into disease mechanisms and identifies potential therapeutic targets for modification.
The neuroinflammatory landscape in PSP involves:
Microglial activation in PSP shows a characteristic regional distribution that mirrors the pattern of tau pathology:
| Brain Region | Microglial Activation Level | Correlation with Tau |
|---|---|---|
| Globus pallidus | Very high | Strong |
| Subthalamic nucleus | High | Strong |
| Substantia nigra | High | Moderate |
| Brainstem nuclei | High | Moderate |
| Cerebellar dentate nucleus | Moderate-High | Moderate |
| Cerebral cortex | Low-Moderate | Weak |
The basal ganglia, particularly the globus pallidus and subthalamic nucleus, show the most pronounced microglial activation in PSP [3]. This contrasts with Alzheimer's disease, where microglial activation is most prominent in cortical regions, and with corticobasal degeneration, where activation is more asymmetric and cortical.
Microglia in PSP predominantly exhibit an M1-like pro-inflammatory phenotype, characterized by:
This M1 predominance differs from corticobasal degeneration, where a mixed M1/M2 phenotype is observed, and from Alzheimer's disease, where disease-associated microglia (DAM) or microglia-neurodegeneration (MGnD) phenotypes are prominent [4].
Translocator protein (TSPO) positron emission tomography (PET) provides in vivo evidence of neuroinflammation in PSP:
| Disease | TSPO Binding Pattern | Relative Intensity |
|---|---|---|
| PSP | Basal ganglia > brainstem > cortex | High |
| CBD | Asymmetric cortical > basal ganglia | Moderate-High |
| AD | Cortical > hippocampus | Moderate |
| PD | Substantia nigra > basal ganglia | Low-Moderate |
These imaging findings confirm that neuroinflammation in PSP has a distinct anatomical distribution that aligns with the characteristic tau pathology pattern [5].
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a receptor expressed on microglia that plays a critical role in microglial homeostasis and phagocytosis. Rare variants in TREM2 increase Alzheimer's disease risk substantially [6].
The role of TREM2 in PSP differs from Alzheimer's disease:
The weaker TREM2 association in PSP suggests that microglial dysfunction in PSP may occur through different pathways than in AD, potentially related to tau-driven microglial activation rather than amyloid-driven mechanisms [7].
Elevated levels of pro-inflammatory cytokines are detected in PSP:
| Biomarker | PSP Change | Clinical Relevance |
|---|---|---|
| YKL-40 | Elevated | Disease progression marker |
| sTREM2 | Variable | Reflects microglial activation |
| Neurofilament light chain (NfL) | Elevated | Disease severity |
| Tau (total and phosphorylated) | Elevated | Pathology burden |
YKL-40, a chitinase-3-like protein produced by activated microglia and astrocytes, shows particular promise as a biomarker in PSP, correlating with disease severity and progression [8].
Astrocytes in PSP exhibit distinctive changes:
The complement system is increasingly recognized in PSP pathogenesis:
Complement proteins may contribute to tau pathology through:
| Gene/Protein | Role in PSP Neuroinflammation |
|---|---|
| TREM2 | Microglial receptor, risk gene |
| TYROBP (DAP12) | TREM2 signaling adaptor |
| CSF1R | Microglial proliferation factor |
| IL1B | Pro-inflammatory cytokine |
| IL6 | Pro-inflammatory cytokine |
| TNF | Pro-inflammatory cytokine |
| CHI3L1 (YKL-40) | Microglial activation marker |
| GFAP | Astrocyte activation marker |
| C1Q | Complement component |
| C3 | Complement component |
Yang et al. (2024) characterized CSF cytokine profiles in PSP vs other tauopathies [9]:
| Cytokine | PSP | CBD | AD | Clinical Correlation |
|---|---|---|---|---|
| IL-1β | Elevated | Elevated | High | Disease severity |
| IL-6 | Moderate | Moderate | High | Progression rate |
| TNF-α | Elevated | Elevated | Moderate | Cognitive decline |
| YKL-40 | High | High | Moderate | Brain atrophy |
Recent developments in neuroinflammation-targeted therapies for PSP: